Ivermectin
Active ingredient · 2 therapeutic classes
Sold as ROSIVER · STROMECTOL
- Drug class
- Avermectines
- Availability
- Prescription and OTC
- Routes
- Oral, Topical
- Markets covered
- 3
- Products on record
- 21
- FDA reports (12 mo)
- 488
Overview
Ivermectin is an active pharmaceutical ingredient in the Avermectines group (P02CF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 11 | May 29, 2026 |
| US United States | FDA | 6 | March 3, 2026 |
| CA Canada | Health Canada | 4 | May 20, 2026 |
GBUnited Kingdom· MHRA
11 products
Uses
• Treatment of gastrointestinal strongyloidiasis (anguillulosis). • Treatment of suspected or diagnosed microfilaraemia in patients with lymphatic filariasis due to Wuchereria bancrofti. • Treatment of human sarcoptic scabies. Treatment is justified when the diagnosis of scabies has been established clinically and/or by parasitological examination.
Without formal diagnosis treatment is not justified in case of pruritus. Official guidelines should be taken into consideration. Official guidelines will normally include WHO and public health authorities’ guidelines.
How to take
USUnited States· FDA
6 products
Uses
INDICATIONS AND USAGE
, nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (See CLINICAL PHARMACOLOGY, Clinical Studies ).
Onchocerciasis Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa.
The comparative studies used diethylcarbamazine citrate (DEC-C).
NOTE:
Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.
CACanada· Health Canada
4 products
Uses
1 Pediatrics Pediatrics (less than 15 kg): Safety and effectiveness of STROMECTOL® in pediatric patients weighing less than 15 kg has not been established (See 7. WARNINGS and PRECAUTIONS). 2 Geriatrics Geriatrics (≥65 years of age): Evidence from clinical studies and experience in the geriatric population has not identified differences in responses between the elderly and younger patients.
(See 7. WARNINGS and PRECAUTIONS).
How to take
Drug interactions
Known interactions involving Ivermectin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL202540095 · revised February 20, 2026
- [2]FDA DailyMed · 014e33e7-c07d-4f… · revised October 5, 2023 [PDF]
- [3]Health Canada (DPD) · 02480557 · revised January 5, 2026
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.